drugset / Trial / NCT05382806

Reversal of Remimazolam by a Single Dose of Flumazenil

NCT05382806

Completed 224 enrolled Konkuk University Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Remimazolam, a brand-new sedative which has benzodiazepine property. It is an ultra-short acting sedative and regarded as a proper drug for procedural sedation.

Timeline

Start
2022-08-02
Primary completion
2023-05-10
Completion
2023-05-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Flumazenil Small molecule 0.2 mg

Indications

No indication recorded.